There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM – Research Report) and Baxter International (BAX – Research Report) with bullish sentiments.
Mirum Pharmaceuticals (MIRM)
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Friday at $25.58.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $53.83 average price target, representing an 117.6% upside. In a report issued on May 5, Robert W. Baird also maintained a Buy rating on the stock with a $35.00 price target.
Baxter International (BAX)
In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Baxter International, with a price target of $90.00. The company’s shares closed last Friday at $73.23.
According to TipRanks.com, Marcus is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Baxter International with a $90.40 average price target, implying a 23.6% upside from current levels. In a report issued on May 17, Citigroup also maintained a Buy rating on the stock with a $85.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MIRM:
- Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Ulta Beauty (ULTA) and Foot Locker (FL)
- Analysts Are Bullish on These Technology Stocks: Anterix (ATEX), Health Catalyst (HCAT)
- Maxim Group Reaffirms Their Buy Rating on Globus Maritime (GLBS)
- Elys Game Technology (ELYS) Gets a Buy Rating from Maxim Group
- Shore Capital Sticks to Its Buy Rating for Close Brothers Group (CBGPF)